



Transgene Expression and Transposition Efficiency of Two-Component Sleeping Beauty Transposon Vector Systems Utilizing Plasmid or mRNA Encoding the Transposase

Natalie Tschorn^{1,2} · Yasemin van Heuvel^{1,2} · Jörn Stitz¹ 

Received: 26 October 2022 / Accepted: 13 December 2022 / Published online: 22 December 2022
© The Author(s) 2022

Abstract

The use of two-component transposon plasmid vector systems, namely, a transposase construct and a donor vector carrying the gene of interest (GOI) can accelerate the development of recombinant cell lines. However, the undesired stable transfection of the transposase construct and the sustained expression of the enzyme can cause genetic instability due to the re-mobilization of the previously transposed donor vectors. Using a *Sleeping Beauty*-derived vector system, we established three recombinant cell pools and demonstrate stable integration of the transposase construct and sustained expression of the transposase over a period of 48 days. To provide an alternative approach, transcripts of the transposase gene were generated in vitro and co-transfected with donor vector plasmid at different ratios and mediating high GOI copy number integrations and expression levels. We anticipate that the use of transposase mRNA will foster further improvements in future cell line development processes.

Keywords Transposon vector · *Sleeping Beauty* · mRNA transfection · Transposition · Transgene expression · Producer cell line

Introduction

Transposon vector technology can be used to mediate highly efficient stable gene transfer allowing for the rapid establishment of transgenic cells and is thus utilized in gene therapeutic strategies as well as the development of cell lines for the production of biologics [1–4]. Two-component plasmid vector systems are most frequently used for non-therapeutic applications derived from *Sleeping Beauty* and *PiggyBac* encompassing a transposase encoding vector and a separate donor vector containing the expression cassette with the gene of interest (GOI) flanked by the inverted terminal repeats (ITRs) [5, 6]. The expressed transposase enzyme recognizes specific sequences in the ITRs and subsequently cuts

out the ITR-flanked expression cassette from the donor vector plasmid and integrates the linear DNA fragment into the target cell genome. This event called transposition thus facilitates stable gene integration via a cut and paste-mechanism [7, 8]. Transposition mediated by *Sleeping Beauty*-derived transposon vectors can mediate the integration of GOIs at high copy numbers per genome and enable sustained expression [9]. When the expression of the GOI in a transposon vector is coupled to a selectable reporter gene such as antibiotic resistance genes, highly productive cell pools can be established in a couple of days and weeks. This approach circumvents the time-consuming establishment and screening of cell clones to reach high productivity [10–12].

The optimal ratio of donor vector and transposase vector is crucial for efficient transposition. A phenomenon called overproduction inhibition (OPI) caused by larger amounts of transposase enzyme appears to decrease transposition activity [13, 14]. Moreover, *Sleeping Beauty* vector-mediated transposition efficiencies vary in different cell lines and types from a range of donor species [10, 11]. This requires the optimization of transfection protocols and the careful titration of donor to transposase construct ratio to obtain high transgenic rates and GOI copy numbers per cell as a

✉ Jörn Stitz
joern.stitz@th-koeln.de

¹ Research Group Medical Biotechnology & Bioengineering, Faculty of Applied Natural Sciences, TH Köln–University of Applied Sciences, Campusplatz 1, 51376 Leverkusen, Germany

² Institute of Technical Chemistry, Leibniz University Hannover, Callinstraße, 530167 Hannover, Germany

result of transposition [13, 15–17]. However, as plasmids are transfected, also stable transfection events occur, namely, the unintended integration of the donor vector including the bacteria-derived backbone and the transposase construct. Especially the undesirable integration of the transposase gene and sustained expression of the transposase enzyme can mediate the mobilization of transposed donor vector cassettes resulting in either the reintegration into new *loci* or the degradation of the mobilized DNA fragments [18]. This genetic instability in the target cell line can thus lead to a loss of productivity.

Consequently, we here established three recombinant cell pools using co-transfection of donor and transposase plasmids and subsequent selection pressure and examined transposase gene integration and expression over a period of 48 days. To circumvent the use of transposase encoding plasmids, the *SB100x* transposase gene of *Sleeping Beauty* was transcribed in vitro into mRNA as previously described by Bire et al. [19], who established this methodology for *PiggyBac*-derived vectors. Human HEK293 cells were either co-transfected with a constant amount of donor vector and the *SB100x* transcripts in different ratios or, alternatively, with an optimized quantity of transposase plasmid construct. Recombinant cell pools were established and analyzed for transgene expression levels and vector copy numbers resulting for transposition and stable transfection, respectively.

Materials and Methods

Cells

Adherent human embryonic kidney HEK293 cells (ATCC CRL-3216) were grown in high glucose (4.5 g/L) Dulbecco's modified Eagle's medium (DMEM) supplemented with 2 mM L-Glutamine and 10% fetal bovine serum (FBS); Gibco, Dreieich, Germany). Cells were expanded at 37 °C in a humidified atmosphere at 5% CO₂. For passaging, cells were detached using 1 mM Ethylenediaminetetraacetic acid (EDTA) in phosphate-buffered saline (PBS). Prior to seeding, cell count was determined using an automated cell counter (fluidlab R-300; Anvajo, Dresden, Germany).

Plasmids

The donor vector SB-EGFP-IpW and transposase expression plasmid CMV-SB100x were previously described by Berg et al. [11, 20]. Donor vector SB-VEGF-IpW was constructed by linearizing SB-EGFP-IpW upon restriction using the enzymes *EcoRV* and *XbaI* removing the enhanced green fluorescence protein (EGFP) encoding fragment and inserting instead an accordingly digested human codon-optimized

sequence encoding human vascular endothelial growth factor (VEGF; Genscript, Piscataway Township, NJ, USA).

Transfection and Selection of HEK293 Cells

HEK293 cells were transfected using TransIT®-LT1 transfection reagent (Mirus, Madison, WI, USA) according to manufacturer's instructions. On the day of transfection, 5×10^5 cells were seeded in 2 mL per well using six-well plates (Nunc, Wiesbaden, Germany). Cells were co-transfected in triplicate with 2.5 µg of SB-VEGF-IpW and 250 ng of transposase vector CMV-SB100x corresponding to a ratio of 1:1/10. Two days post transfection, cell pools were subjected to a selection pressure of 0.5 µg/mL of puromycin (InvivoGen, Toulouse, France), which was increased stepwise to a final concentration of 10 µg/mL over a period of 48 days.

Detection of Transposase Coding Sequence in Genomic DNA

Genomic DNA of recombinant cell pools was harvested using the EchoLUTION Cell Culture DNA Kit (BioEcho, Cologne, Germany). Equivalents of 10,000 genomes (60 ng) of genomic DNA originating from transfected HEK293 cells and naïve cells serving as a negative control were used to perform genomic PCR using the Q5® High-Fidelity DNA Polymerase following the manufacturer's instructions (NEB, Ipswich, MA, USA). 0.001 pg of the transposase expression plasmid (equivalent to 10² copies) served as a positive control. In parallel, serial dilutions of transposase expression plasmid mixed with 60 ng genomic DNA of naïve HEK293 cells were prepared to serve as a reference standard. Using the oligonucleotides gDNA_SB100x-for: 5'-CTAGCGTGCAGACAATCGTGAGGAAGTACAAG-3' and gDNA_SB100x-rev: 5'-TGGCCCTCGCAGACAGCGAATTAATTGAATTC-3' generated amplicons of a size of 436 bp. PCR was performed employing an initial denaturation step of 30 s at 98 °C, followed by 35 cycles of denaturation for 10 s at 98 °C, annealing for 15 s at 63 °C and elongation for 15 s at 72 °C, and a final extension step for 2 min at 72 °C.

Detection of SB100x Transcripts

RNA of transfected HEK293 cells was harvested using the RNeasy Mini Kit (Qiagen, Hilden, Germany) according to manufacturer's instructions. Concentration of purified RNA was determined utilizing a NanoQuant Plate™ Reader (Tecan Trading AG, Männedorf, Switzerland). Purified RNA (1 µg) was subsequently reverse transcribed to cDNA using the LunaScript® RT SuperMix Kit (NEB, Ipswich, MA USA). For transposase gene detection, PCR was performed with 2 µL of cDNA solution serving as a template and

(Thermo Scientific, Waltham, MA, USA). DNA-free samples and genomic DNA of naïve HEK293 cells served as negative controls. Serial dilutions of the reference VCN-standard plasmid containing WPRE, ampicillin resistance gene (*Amp^R*), and PTBP2 sequences were used for standardization. Details of the cloning strategy are available upon reasonable request. Statistical significance was determined using the GraphPad Prism software (GraphPad software; San Diego, CA; USA) utilizing the 1-way-ANOVA test.

Results

Detection of the SB100x Gene in Genomic DNA of Transgenic HEK293 Cells

Recombinant cell pools were established upon co-transfection with the donor vector SB-VEGF-IpW and transposase vector CMV-SB100x illustrated in Fig. 1 and expanded for 48 days under escalating selection pressure reaching a final puromycin concentration of 10 µg/mL at day 38. To monitor integration of the *SB100x* gene into cell genomes, genomic DNA of recombinant cell pools was isolated at different time points of cultivation. Genomic DNA of naïve HEK293 cells and a template-free sample (H₂O) served as negative controls. PCR was conducted using *SB100x*-specific primers generating amplicons with a size of 436 bp. In parallel, serial dilutions of the transposase expression plasmid were mixed with 60 ng of genomic DNA of naïve HEK293 cells equivalent to 10,000 genomes to assess PCR sensitivity. As shown in Fig. 2 and with a sensitivity of 10 copies in 1000 genomes, *SB100x* genes were detectable throughout the entire cultivation and selection period of 48 days post transfection. Signal intensities, and thus the *SB100x* gene frequency, decreased from seven to 48 days post transfection indicating yet *SB100x* gene copy numbers of $> 10^2$ and $< 10^3$ integrated in 10,000 genomes.

Detection of SB100x Transcripts in Recombinant HEK293 Cells

To assess whether integrated transposase genes also mediated the expression of transcripts, RNA of recombinant cell pools was isolated 17 and 48 days post transfection. RNA was subsequently transcribed into cDNA and PCR was conducted employing *SB100x*-specific oligonucleotides. As an internal reference, primers specific for the amplification of GAPDH were used to ensure that similar amounts of RNA templates were applied. As shown in Fig. 3, transposase transcription was readily detected 17 and 48 days post transfection. Amplicon signal intensity decreased from day 17 to day 48, while GAPDH amplification remained constant. This demonstrated the sustained expression of transposase resulting from the unintended stable integration of the respective expression construct.

Detection of SB100x Transcripts in Recombinant HEK293 Cells Using mRNA for Transposition

To prevent undesired integration of the transposase gene into the target genome, cDNA of *SB100x* was transcribed in vitro into SB100x-mRNA for subsequent co-transfection with the donor vector SB-EGFP-IpW (Fig. 1). Different ratios of SB100x-mRNA to donor vector were co-transfected into HEK293 cells to determine the optimal condition facilitating efficient transposition. Two and 16 days post transfection, genomic DNA was isolated and subjected to PCR using *SB100x*-specific oligonucleotides. As shown in Fig. 4A and two days post transfection, the transposase gene was detectable in all cell pools co-transfected with SB100x-mRNA or plasmid SB100x. Detected signal intensities decreased with higher dilution of transfected SB100x-mRNA. This indicated the contamination of SB100x-mRNA with the IVTRup-SB100x-derived amplicon DNA. However, after 16 days of cultivation




Fig. 1 Schematic illustration of the genetic elements of transposon and transposase vector constructs. (a) A CMV promoter/enhancer element (P_{CMV}) drives expression of the donor vectors and (b) the plasmid-based helper vector construct. The expression cassettes of the donor plasmids encompass the reporter gene enhanced green fluorescent protein (*egfp*) or vascular endothelial growth factor (*vegf*) followed by a synthetic intron (IVS) and an internal ribosome entry site (IRES). Thus, the puromycin resistance gene (*puro^R*) allows also for the selection of cells expressing of the other reporter gene and is

followed by the woodchuck hepatitis posttranscriptional regulatory element (WPRE) and a polyadenylation signal (p(A)) of the bovine growth hormone (bGH). The expression cassettes of the donor vectors are flanked by inverted terminal repeats (ITRs) of *Sleeping Beauty* (SB). The transposase construct CMV-SB100x encodes the human codon-optimized transposase variant *SB100x*. (c) The SB100x-mRNA comprises the transposase coding sequence and is flanked by untranslated regions (UTRs). The 5'Cap stabilizes the mRNA and protects it from degradation




Fig. 2 Detection of *SB100x* coding sequences in genomic DNA. **A** Different amounts of plasmid CMV-*SB100x* were mixed with 60 ng genomic DNA of naïve HEK293 cells equivalent to 10,000 genomes to determine the sensitivity of detection. A PCR reaction mixture without plasmid DNA template served as a negative control (H_2O). **B** Exemplarily, one representative data set of the detection of *SB100x* gene in genomic DNA of recombinant HEK293 cell pools performed in triplicate is shown. Genomic DNA was isolated from selected

cell pools upon co-transfection of donor vector SB-VEGF-IpW and transposase expression construct CMV-*SB100x* at different days post transfection to investigate transposase gene integration. 0.001 pg of the transposase vector mixed with 60 ng genomic DNA of naïve HEK293 cells equivalent to 10,000 genomes served as a positive control (10^2 copies). Genomic DNA of naïve HEK293 cells and template-free samples (H_2O) served as negative controls




Fig. 3 Detection of *SB100x* transcripts in HEK293 cell pools. RNA of selected cell pools was isolated 17 and 48 days post transfection (dpt) and served as templates for cDNA synthesis. Equivalent volumes of synthesized cDNA were used for the amplification of DNA fragments of the *SB100x* coding sequences. GAPDH amplification served as an internal and positive control. RNA isolated from naïve HEK293 cells and template-free samples (H_2O) served as negative controls. Data shown are representative results of experiments conducted in triplicate

under constant selection pressure, the transposase gene was exclusively still detectable in genomic DNA of cells co-transfected with plasmid *SB100x*. Cell pools transfected with *SB100x*-mRNA showed no longer a contamination with *SB100x* DNA at a sensitivity of detection of 10^2 copies per 10,000 genomes. It could therefore be assumed, that the IVTRup-*SB100x* plasmid was detected at 2 days post transfection in its epichromosomal form and did not stably integrate into the cell genomes at high frequency.

In parallel and to examine transposase expression, RNA was isolated and transcribed in vitro into cDNA for subsequent PCR after 16 days of cultivation. Transposase gene expression was readily detected only in samples of cells co-transfected with plasmid *SB100x*. In contrast and underscoring the findings employing genomic PCR, no

transposase transcripts were detected in cells transfected with *SB100x*-mRNA.

FACS Analysis 16 Days Post Transfection Using *SB100x*-mRNA

To investigate the optimal ratio of donor vector to *SB100x*-mRNA for elevated transposition efficiencies resulting in high reporter gene expression levels, cells were subjected to flow cytometric analysis to determine EGFP mean fluorescence intensity (MFI) 16 days post transfection under constant selection pressure. As shown in Fig. 5A, cells transfected exclusively with the donor construct revealed the lowest MFI (987 ± 112) followed by the cell pools transfected with *SB100x*-mRNA at a ratio of 1:1/10 (1592 ± 79) and 1:1/20 (1175 ± 32). The highest MFI showed the cells transfected with plasmid-based transposase construct (3595 ± 104). Cells transfected with mRNA at a ratio of 1:1; 1:1/2 and 1:1/5 exhibited comparable and second highest mean fluorescence intensities (2583 ± 74 ; 2490 ± 0 ; 2367 ± 49).

Assessment of Vector Copy Number

Vector copy numbers (VCNs) stably integrated in host cell genomes were examined 16 days post transfection employing TaqMan® qPCR. VCNs were determined using WPRE-specific primers probes binding within the donor vector expression cassette. PTBP2 primers served as internal reference. As shown in Fig. 5B, all cell pools transfected with *SB100x*-mRNA and cells transfected with the donor construct only reached a copy number of three copies or more of the donor vector. Co-transfection of the donor vector and




Fig. 4 Detection of the transposase coding region in genomic DNA and RNA preparations of HEK293 cells after co-transfection. **A** Different ratios of donor vector SB-EGFP-*IpW* to SB100x-mRNA were transfected into HEK293 cells in duplicate and genomic DNA was isolated 2 and 16 days post transfection (dpt) for subsequent sensitive PCR analysis. In addition, co-transfections of the donor vector and the transposase plasmid CMV-SB100x and transfection with the donor vector exclusively were conducted. Transposase plasmid mixed with 60 ng genomic DNA of naïve HEK293 cells equivalent

to 10,000 genomes served as positive control (10² copies). Genomic DNA of naïve HEK293 cells and template-free samples (H₂O) served as negative controls. **B** Detection of *SB100x* transcripts in HEK293 cells. RNA of cell pools was isolated 16 dpt. Equivalent volumes of synthesized cDNA were used for the amplification of DNA fragments of the *SB100x* coding sequence. Amplification of GAPDH served as an internal positive control. Naïve HEK293 cells and template-free samples (H₂O) served as negative controls. Data shown are representative results of experiments conducted in duplicate




Fig. 5 Flow cytometric analysis of HEK293 cells and determination of vector copy number (VCN) per genome from different cell pools 16 days post transfection after constant selection performed in duplicate. **A** HEK293 cells were co-transfected with different ratios of donor vector SB-EGFP-*IpW* to SB100x-mRNA and were analyzed for mean fluorescence intensity of EGFP expression (EGFP-MFI) employing flow cytometry. In addition, cells transfected with the donor vector only and co-transfected with the vector CMV-SB100x were analyzed. Mean values are indicated and error bars represent standard deviations. (*) A P value ≤ 0.05 is indicated for the ratios Donor+mRNA 1:1 and Donor+mRNA 1:1/5. The difference of mean EGFP-MFI values of ratios Donor+mRNA 1:1 and

Donor+mRNA 1:1/2 is not statistically significant (n.s.; using the one-way ANOVA analysis). **B** Determination of VCN 16 days post transfection. Genomic DNA was isolated of HEK293 cell pools transfected with different amounts of SB100x-mRNA or transposase expression plasmid CMV-SB100x and subjected to Taqman@-qPCR using oligonucleotides allowing for the amplification of DNA fragments of WPRE in the donor vector and ampicillin (Amp^R) present in the backbones of all constructs used. An additional primer/probe set amplifying the *ptbp2* gene was used as an internal reference. Mean values are shown and error bars represent standard deviations resulting from two independent experiments

plasmid-based transposase resulted in a mean integration of six transposon vector copies.

To investigate whether integrated VCNs were a consequence of stable donor plasmid transfection or transposition, qPCR using ampicillin-specific primers was conducted allowing for the detection of plasmid backbones of donor vector, transposase construct, and in some cases pUC18 used as fill-up DNA. Transfection with SB100x-mRNA with a ratio of 1:1 and 1:1/2 to donor vector SB-EGFP-IpW revealed the lowest amount of stably integrated plasmid with a mean plasmid integration of around 1 per cells (1.1 ± 0.0 ; 0.9 ± 0.2). Cells transfected with SB100x-mRNA and donor vector at a ratio of 1:1/5 as well as co-transfection with the plasmid CMV-SB100x yielded about two plasmid copy numbers (1.5 ± 0.2 ; 1.4 ± 0.3), respectively. Transfection of mRNA in a ratio of 1:1/10 and 1:1/20 and transfection with the donor vector only led to the integration of around three to four copies of ampicillin resistance genes as a result of undesired stable transfection.

Discussion

Transposon vector technology has fostered the establishment of recombinant cell lines for the production of biologics, vaccine candidates, and viral vector particles [1]. However, when the transposase is expressed from plasmid DNA, the undesired integration as a result from stable transfection and sustained expression of the transposase gene may cause genetic instability of selected polyclonal recombinant cell lines due to ongoing transposition events.

We thus investigated the integration and expression of the transposase gene after co-transfection of a donor vector and a transposase construct followed by subsequent selection of three stable cell pools. HEK293 cells were co-transfected with the donor vector SB-VEGF-IpW and transposase expression vector CMV-SB100x in a ratio of 1:1/10. The ratio was previously optimized in our laboratory for efficient transposition in HEK293 cells resulting in high expression of the gene of interest. Two days post transfection, cells were subjected to expansion in the presence of increasing concentrations of puromycin and were cultivated until 48 days post transfection. Genomic DNA of recombinant cell pools was isolated at different time points and examined for transposase gene integration. Employing sensitive PCR, cell pools revealed *SB100x* gene integration over the entire period of 48 days with an approximate VCN of $> 10^2$ per 10,000 genomes. The much higher VCN at day 7 and 10 can be attributed to high amounts of unintegrated epichromosomal plasmid shortly after transfection.

To investigate whether the integrated *SB100x* genes also mediated the expression of the respective *SB100x* transcripts, RNA of recombinant cells was isolated 17 and

48 days post transfection and subjected to RT-PCR analysis. Sustained transposase gene expression was readily detected at both time points. Signal intensity decreased from day 17 to day 48 most likely indicating gene silencing due to DNA methylation attracted by the bacteria-derived sequences in the plasmid backbone [23, 24].

To circumvent the use of transposon encoding plasmid DNA, we transcribed the *SB100x* DNA sequence in vitro into mRNA and co-transfected different ratios of donor vector to SB100x-mRNA with the transposon vector plasmid SB-EGFP-IpW into HEK293 cells in duplicate. To compensate for reduced mRNA amounts, samples were supplemented with the fill-up plasmid pUC18. Control cells were transfected with the donor vector—plus fill-up pUC18—and together with the transposase construct CMV-SB100x, respectively. Transgenic cells were continuously selected in the presence of puromycin. Genomic DNA of selected cell pools were again analyzed for the presence of the *SB100x* gene using sensitive PCR. The transposase gene was readily detected in all samples taken 2 days post transfection including the mRNA co-transfected cells. It is likely to assume that this was caused by a contamination with the PCR amplicon generated from parental construct IVTRup-SB100x used for in vitro transcription of the mRNA. The protocol used here should therefore in future extend the time for DNase I treatment and elevate the enzyme concentration to eliminate future contaminations. However, the contaminating PCR amplicon must mostly have remained epichromosomal since all samples of mRNA co-transfected cells were tested negative at 16 days post transfection. In contrast and yet again, cells co-transfected with the plasmid CMV-SB100x integrated transposase genes were readily detected. Using RT-PCR analysis, only these cells were also shown to express the transposase genes.

To assess efficient reporter gene expression and donor vector transposition, cell pools were also examined for EGFP expression and vector copy numbers 16 days post transfection employing FACS analysis and quantitative Taqman® qPCR, respectively. Cell pools co-transfected with transposase vector CMV-SB100x revealed the highest EGFP-MFI followed by cell pools transfected with SB100x-mRNA in a ratio of 1:1, 1:1/2, and 1:1/5. Cell pools co-transfected mRNA with a ratio of 1:1/10 and 1:1/20 revealed comparable mean fluorescence intensities to donor only transfected cell pools. This showed that reporter gene expression could be increased by transfecting more transposase mRNA but reached a maximum using a ratio of 1:1/5.

To examine whether high EGFP expression levels were a result of efficient transposition, Taqman® qPCR was performed using primers amplifying the mRNA-stabilizing element WPRE with in the transgene expression cassette of the donor vector and Amp^R-specific primers able to amplify from the backbones of all plasmids used in this

study, namely, SB-EGFP-IpW, CMV-SB100x, and pUC18. As expected from the highest expression level of EGFP, cells co-transfected with the donor vector and the CMV-SB100x expression plasmid revealed also the highest VCN of about 6 for the transposon vector, while only less than 2 copies of the plasmid backbones were detected indicating efficient transposition. The cell pool co-transfected with plasmid-based transposase generated copy numbers of about 6 copies per cell and is in accordance with the results of Kolacsek et al. [25].

Cells co-transfected with the donor vector and fill-up plasmid revealed lower VCN of around 4 for the donor vector, but even slightly higher amounts of integrated Amp^R genes demonstrating that the integrations resulted from stable transfection and due to the adjacent bacterial sequence were prone to gene silencing [7, 8, 26]. Similar patterns were observed in cells co-transfected with transposase RNA at ratios of 1:1/10 and 1:1/20, respectively. However, with the high amount of fill-up plasmid used here to compensate decreasing vector component DNA concentrations, it is very likely that a large proportion of plasmid backbone detected originated from pUC18 integrations. This would in turn mean that most transposon vector copies resulted from transposition events and would explain higher EGFP expression levels as compared to the control cells. Cells transfected with RNA to plasmid ratios 1:1, 1:1/2, and 1:1/5 revealed much lower amounts of backbone sequences ranging from 1 to 2 but similar donor vector copies of about 3 per genome, and thus mostly integrated by transposition. This supports the findings of comparable high expression the EGFP transgene.

The elevated copy numbers using CMV-SB100x were presumably a result of the prolonged expression of the transposase gene over some of days as compared to the utilization of transposase mRNA, which only last for a couple of hours [19]. We assume this could be compensated conducting first co-transfections of donor vector and transposase mRNA followed by repeated serial transfections of only the mRNA e.g., at two or three successive days. During this time period, donor plasmid should still be available in sufficient quantities in the cells to enable efficient transposition. In summary, we anticipate that the avoidance of undesired transposase gene integration into the host cell genome, and thus sustained expression, using transposase IVT mRNA transcripts will be utilized in future cell line development processes.

Acknowledgements We are indebted to Stefanie Schatz for expert technical support. This work was supported by the German Federal Ministry of Education and Research, funding program Forschung an Fachhochschulen, contract number 13FH242PX6 to JS.

Author Contributions Conceptualization: NT, JS; Methodology: NT, YvH; Formal analysis and investigation: NT; Writing-original draft preparation: NT; Supervision of the project: JS.

Funding Open Access funding enabled and organized by Projekt DEAL.

Declarations

Competing Interests The authors declare that they have no conflict of interest.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

References

1. Wei, M., Mi, C.-L., Jing, C.-Q., & Wang, T.-Y. (2022). Progress of transposon vector system for production of recombinant therapeutic proteins in mammalian cells. *Frontiers in Bioengineering and Biotechnology*. <https://doi.org/10.3389/fbioe.2022.879222>
2. Kowarz, E., Löscher, D., & Marschalek, R. (2015). Optimized Sleeping Beauty transposons rapidly generate stable transgenic cell lines. *Biotechnology Journal*, 10, 647–653. <https://doi.org/10.1002/biot.201400821>
3. Hu, J., Zhang, P., Wang, M., et al. (2012). A transgenic Bm cell line of piggyBac transposon-derived targeting expression of humanized glycoproteins through *N*-glycosylation. *Molecular Biology Reports*, 39, 8405–8413. <https://doi.org/10.1007/s11033-012-1692-y>
4. Michael, I. P., & Nagy, A. (2018). Inducible protein production in 293 cells using the piggyBac transposon system. *Methods in Molecular Biology*, 1850, 57–68. https://doi.org/10.1007/978-1-4939-8730-6_5
5. Geurts, A. M., Yang, Y., Clark, K. J., et al. (2003). Gene transfer into genomes of human cells by the Sleeping Beauty transposon system. *Molecular Therapy*, 8, 108–117. [https://doi.org/10.1016/S1525-0016\(03\)00099-6](https://doi.org/10.1016/S1525-0016(03)00099-6)
6. Ding, S., Wu, X., Li, G., et al. (2005). Efficient transposition of the piggyBac (PB) transposon in mammalian cells and mice. *Cell*, 122, 473–483. <https://doi.org/10.1016/j.cell.2005.07.013>
7. Ivics, Z., Hackett, P. B., Plasterk, R. H., & Izsvák, Z. (1997). Molecular reconstruction of Sleeping Beauty, a *Tc1*-like transposon from fish, and its transposition in human cells. *Cell*, 91, 501–510. [https://doi.org/10.1016/s0092-8674\(00\)80436-5](https://doi.org/10.1016/s0092-8674(00)80436-5)
8. Handler, A. M., McCombs, S. D., Fraser, M. J., & Saul, S. H. (1998). The lepidopteran transposon vector, piggyBac, mediates germ-line transformation in the Mediterranean fruit fly. *Proceedings of the National Academy of Sciences*, 95, 7520–7525. <https://doi.org/10.1073/pnas.95.13.7520>
9. Johnen, S., Izsvák, Z., Stöcker, M., et al. (2012). Sleeping beauty transposon-mediated transfection of retinal and iris pigment epithelial cells. *Investig Ophthalmology Vis Sci*, 53, 4787. <https://doi.org/10.1167/iovs.12-9951>
10. Berg, K., Schäfer, V. N., Bartnicki, N., et al. (2019). Rapid establishment of stable retroviral packaging cells and recombinant susceptible target cell lines employing novel transposon vectors

- derived from Sleeping Beauty. *Virology*, 531, 40–47. <https://doi.org/10.1016/j.virol.2019.02.014>
11. Berg, K., Schäfer, V. N., Tschorn, N., & Stitz, J. (2020). Advanced establishment of stable recombinant human suspension cell lines using genotype-phenotype coupling transposon vectors. *Methods in Molecular Biology*, 2070, 351–361. https://doi.org/10.1007/978-1-4939-9853-1_20
 12. Balasubramanian, S., Rajendra, Y., Baldi, L., et al. (2016). Comparison of three transposons for the generation of highly productive recombinant CHO cell pools and cell lines. *Biotechnology and Bioengineering*, 113, 1234–1243. <https://doi.org/10.1002/bit.25888>
 13. Grabundzija, I., Irgang, M., Mátés, L., et al. (2010). Comparative analysis of transposable element vector systems in human cells. *Molecular Therapy*, 18, 1200–1209. <https://doi.org/10.1038/mt.2010.47>
 14. Lohe, A. R., & Hartl, D. L. (1996). Autoregulation of mariner transposase activity by overproduction and dominant-negative complementation. *Molecular Biology and Evolution*, 13, 549–555. <https://doi.org/10.1093/oxfordjournals.molbev.a025615>
 15. Izsvák, Z., Ivics, Z., & Plasterk, R. H. (2000). Sleeping Beauty, a wide host-range transposon vector for genetic transformation in vertebrates 1 Edited by J. Karn. *Journal of Molecular Biology*, 302, 93–102. <https://doi.org/10.1006/jmbi.2000.4047>
 16. Turchiano, G., Latella, M. C., Gogol-Döring, A., et al. (2014). Genomic analysis of Sleeping Beauty transposon integration in human somatic cells. *PLoS ONE*, 9, e112712. <https://doi.org/10.1371/journal.pone.0112712>
 17. Zayed, H., Izsvák, Z., Walisko, O., & Ivics, Z. (2004). Development of hyperactive Sleeping Beauty transposon vectors by mutational analysis. *Molecular Therapy*, 9, 292–304. <https://doi.org/10.1016/j.ymthe.2003.11.024>
 18. Liang, Q., Kong, J., Stalker, J., & Bradley, A. (2009). Chromosomal mobilization and reintegration of Sleeping Beauty and PiggyBac transposons. *Genesis*, 47, 404–408. <https://doi.org/10.1002/dvg.20508>
 19. Bire, S., Gosset, D., Jégot, G., et al. (2013). Exogenous mRNA delivery and bioavailability in gene transfer mediated by piggyBac transposition. *BMC Biotechnology*, 13, 75. <https://doi.org/10.1186/1472-6750-13-75>
 20. Mátés, L., Chuah, M. K. L., Belay, E., et al. (2009). Molecular evolution of a novel hyperactive Sleeping Beauty transposase enables robust stable gene transfer in vertebrates. *Nature Genetics*, 41, 753–761. <https://doi.org/10.1038/ng.343>
 21. Steinle, H., Behring, A., Schlensak, C., et al. (2017). Concise review: Application of in vitro transcribed messenger RNA for cellular engineering and reprogramming: Progress and challenges. *Stem Cells*, 35, 68–79. <https://doi.org/10.1002/stem.2402>
 22. Eggenschwiler, R., Moslem, M., Fráguas, M. S., et al. (2016). Improved bi-allelic modification of a transcriptionally silent locus in patient-derived iPSC by Cas9 nickase. *Science and Reports*, 6, 1–14. <https://doi.org/10.1038/srep38198>
 23. Riu, E., Chen, Z.-Y., Xu, H., et al. (2007). Histone modifications are associated with the persistence or silencing of vector-mediated transgene expression in vivo. *Molecular Therapy*, 15, 1348–1355. <https://doi.org/10.1038/sj.mt.6300177>
 24. Chen, Z.-Y., Riu, E., He, C.-Y., et al. (2008). Silencing of episomal transgene expression in liver by plasmid bacterial backbone DNA Is independent of CpG methylation. *Molecular Therapy*, 16, 548–556. <https://doi.org/10.1038/sj.mt.6300399>
 25. Kolacsek, O., Krízsik, V., Schamberger, A., et al. (2011). Reliable transgene-independent method for determining Sleeping Beauty transposon copy numbers. *Mobile DNA*, 2, 5. <https://doi.org/10.1186/1759-8753-2-5>
 26. Garrison, B. S., Yant, S. R., Mikkelsen, J. G., & Kay, M. A. (2007). Postintegrative gene silencing within the Sleeping Beauty transposition system. *Molecular and Cellular Biology*, 27, 8824–8833. <https://doi.org/10.1128/mcb.00498-07>

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.